Kronos Bio Inc expected to post a loss of 71  cents a share - Earnings Preview

Kronos Bio

06/05/2022 16:32

* Kronos Bio Inc  KRON.OQ   KRON.O  is expected to show no
change
in quarterly revenue when it reports  results 
    * ​Refinitiv's mean analyst estimate for Kronos Bio Inc is
for a
loss of 71 cents per share. For the same quarter last year, the
company reported a loss of 53 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 5.7%
in the last three months. ​
    * Wall Street's median 12-month price target for Kronos Bio
Inc is
$32.5​, above​ its last closing price of $4.71. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2022  -0.65       -0.66      -0.65     Beat    1.2
 Dec. 31 2022  -1.08       -1.10      -1.13     Missed  -2.9
 Sep. 30 2021  -0.99       -1.01      -0.61     Beat    39.7​
 Jun. 30 2021  -0.59       -0.62      -0.53     Beat    14.8
 ​​Mar.        -0.43       -0.43      -0.48     Missed  -10.7
 31 2021                                                
 Dec. 31 2020  -0.76       -0.79      -0.70     Beat    11.1​
 Sep. 30 2020  -1.47       -1.47      -4.00     Missed  -171.5
 This summary was machine generated May 6 at 15:32 GMT.  All
figures in US dollars  unless otherwise stated